{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:50:14Z","timestamp":1789411814246,"version":"build-2803163510"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,30]]},"DOI":"10.7759\/cureus.87049","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T18:37:22Z","timestamp":1751308642000},"source":"Crossref","is-referenced-by-count":5,"title":["Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitors: Interpreting the Discrepancy Between Clinical Trials and Real-World Data"],"prefix":"10.7759","author":[{"given":"Amalia","family":"Papanikolopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Michalopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos G","family":"Kyriakoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyxeni","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vathiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas","family":"Thomopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriani","family":"Charpidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey JD","year":"2021","unstructured":"Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021, 23:39. 10.1208\/s12248-021-00574-0","journal-title":"AAPS J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1042\/CS20200331","article-title":"Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"135","author":"Baik AH","year":"2021","unstructured":"Baik AH, Tsai KK, Oh DY, Aras MA. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Clin Sci (Lond). 2021, 135:703-24. 10.1042\/CS20200331","journal-title":"Clin Sci (Lond)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca MP","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, et al.. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019, 140:80-91. 10.1161\/CIRCULATIONAHA.118.034497","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015, 373:23-34. 10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert C","year":"2015","unstructured":"Robert C, Long GV, Brady B, et al.. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015, 372:320-30. 10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang DY","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, et al.. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:1721-8. 10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson DB","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al.. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016, 375:1749-55. 10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood SS","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, et al.. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018, 71:1755-64. 10.1016\/j.jacc.2018.02.037","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem JE","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al.. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018, 19:1579-89. 10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon AR","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al.. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022, 43:4229-361. 10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02760-2","article-title":"Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis","volume":"22","author":"Zhang XT","year":"2022","unstructured":"Zhang XT, Ge N, Xiang ZJ, Liu T. Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis. Cancer Cell Int. 2022, 22:363. 10.1186\/s12935-022-02760-2","journal-title":"Cancer Cell Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101383","article-title":"Cardiovascular toxicity following immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"19","author":"Xavier CB","year":"2022","unstructured":"Xavier CB, Lopes CD, Harada G, Peres ED, Katz A, Jardim DL. Cardiovascular toxicity following immune checkpoint inhibitors: a systematic review and meta-analysis. Transl Oncol. 2022, 19:101383. 10.1016\/j.tranon.2022.101383","journal-title":"Transl Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1065510","article-title":"Safety and efficacy of radiotherapy\/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: a systematic review and meta-analysis","volume":"14","author":"Wu J","year":"2023","unstructured":"Wu J, Ni T, Deng R, et al.. Safety and efficacy of radiotherapy\/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: a systematic review and meta-analysis. Front Immunol. 2023, 14:1065510. 10.3389\/fimmu.2023.1065510","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13831","article-title":"Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: a systematic review and meta-analysis","volume":"52","author":"Malaty MM","year":"2022","unstructured":"Malaty MM, Amarasekera AT, Li C, Scherrer-Crosbie M, Tan TC. Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: a systematic review and meta-analysis. Eur J Clin Invest. 2022, 52:e13831. 10.1111\/eci.13831","journal-title":"Eur J Clin Invest"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann J","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, et al.. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022, 43:280-99. 10.1093\/eurheartj\/ehab674","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2018.345","article-title":"The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review","volume":"106","author":"Eriksen MB","year":"2018","unstructured":"Eriksen MB, Frandsen TF. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Libr Assoc. 2018, 106:420-31. 10.5195\/jmla.2018.345","journal-title":"J Med Libr Assoc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny F","year":"2022","unstructured":"Thuny F, Naidoo J, Neilan TG. Cardiovascular complications of immune checkpoint inhibitors for cancer. Eur Heart J. 2022, 43:4458-68. 10.1093\/eurheartj\/ehac456","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga VN","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014, 72:39. 10.1186\/2049-3258-72-39","journal-title":"Arch Public Health"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000910","article-title":"A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients","volume":"86","author":"Ho CC","year":"2023","unstructured":"Ho CC, Wu SL, Tsai HY, Hu YW, Chang YL. A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients. J Chin Med Assoc. 2023, 86:499-505. 10.1097\/JCMA.0000000000000910","journal-title":"J Chin Med Assoc"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1025455","article-title":"Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy","volume":"12","author":"Son C","year":"2022","unstructured":"Son C, Moey MY, Walker PR, Naqash AR, Peach MS, Ju AW. Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy. Front Oncol. 2022, 12:1025455. 10.3389\/fonc.2022.1025455","journal-title":"Front Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2023.10.008","article-title":"Atherosclerotic cardiovascular events in cancer patients treated with immune checkpoint inhibitors: a retrospective cohort study","volume":"33","author":"Tan S","year":"2024","unstructured":"Tan S, Spear E, Sane N, et al.. Atherosclerotic cardiovascular events in cancer patients treated with immune checkpoint inhibitors: a retrospective cohort study. Heart Lung Circ. 2024, 33:721-9. 10.1016\/j.hlc.2023.10.008","journal-title":"Heart Lung Circ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174293","article-title":"Cardiotoxicity secondary to immune checkpoint inhibitors in the elderly: safety in real-world data","volume":"15","author":"Toribio-Garc\u00eda I","year":"2023","unstructured":"Toribio-Garc\u00eda I, Olivares-Hern\u00e1ndez A, Miramontes-Gonz\u00e1lez JP, et al.. Cardiotoxicity secondary to immune checkpoint inhibitors in the elderly: safety in real-world data. Cancers (Basel). 2023, 15:4293. 10.3390\/cancers15174293","journal-title":"Cancers (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1093383","article-title":"Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: a single-center experience","volume":"10","author":"Xiao J","year":"2023","unstructured":"Xiao J, Li X, Wang X, et al.. Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: a single-center experience. Front Cardiovasc Med. 2023, 10:1093383. 10.3389\/fcvm.2023.1093383","journal-title":"Front Cardiovasc Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27604","article-title":"Cardiovascular events after cancer immunotherapy as oncologic emergencies: analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors","volume":"46","author":"Reyes-Gibby CC","year":"2024","unstructured":"Reyes-Gibby CC, Qdaisat A, Ferrarotto R, et al.. Cardiovascular events after cancer immunotherapy as oncologic emergencies: analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors. Head Neck. 2024, 46:627-35. 10.1002\/hed.27604","journal-title":"Head Neck"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-596","article-title":"PD-1 inhibitors-associated myocarditis in non-small cell lung cancer patients","volume":"15","author":"He Y","year":"2023","unstructured":"He Y, Chen W, Cai J, Luo C, Zhou C, Wei L. PD-1 inhibitors-associated myocarditis in non-small cell lung cancer patients. J Thorac Dis. 2023, 15:4606-19. 10.21037\/jtd-23-596","journal-title":"J Thorac Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051145","article-title":"Immune checkpoint inhibitors-associated cardiotoxicity","volume":"14","author":"Li C","year":"2022","unstructured":"Li C, Bhatti SA, Ying J. Immune checkpoint inhibitors-associated cardiotoxicity. Cancers (Basel). 2022, 14:1145. 10.3390\/cancers14051145","journal-title":"Cancers (Basel)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-022-00130-5","article-title":"Cardiotoxicity risk factors with immune checkpoint inhibitors","volume":"8","author":"Brumberger ZL","year":"2022","unstructured":"Brumberger ZL, Branch ME, Klein MW, Seals A, Shapiro MD, Vasu S. Cardiotoxicity risk factors with immune checkpoint inhibitors. Cardiooncology. 2022, 8:3. 10.1186\/s40959-022-00130-5","journal-title":"Cardiooncology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002054","article-title":"Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients","volume":"135","author":"Li Y","year":"2022","unstructured":"Li Y, Wang Y, Li N, et al.. Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients. Chin Med J (Engl). 2022, 135:988-90. 10.1097\/CM9.0000000000002054","journal-title":"Chin Med J (Engl)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.882167","article-title":"Immune checkpoint inhibitor-associated cardiotoxicity in solid tumors: real-world incidence, risk factors, and prognostic analysis","volume":"9","author":"Chen X","year":"2022","unstructured":"Chen X, Jiang A, Zhang R, et al.. Immune checkpoint inhibitor-associated cardiotoxicity in solid tumors: real-world incidence, risk factors, and prognostic analysis. Front Cardiovasc Med. 2022, 9:882167. 10.3389\/fcvm.2022.882167","journal-title":"Front Cardiovasc Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1062858","article-title":"Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors","volume":"9","author":"Torrente M","year":"2022","unstructured":"Torrente M, Blanco M, Franco F, et al.. Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. Front Cardiovasc Med. 2022, 9:1062858. 10.3389\/fcvm.2022.1062858","journal-title":"Front Cardiovasc Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac056","article-title":"Incidence, clinical characteristics, and predictors of cardiovascular immune-related adverse events associated with immune checkpoint inhibitors","volume":"27","author":"Isawa T","year":"2022","unstructured":"Isawa T, Toi Y, Sugawara S, Taguri M, Toyoda S. Incidence, clinical characteristics, and predictors of cardiovascular immune-related adverse events associated with immune checkpoint inhibitors. Oncologist. 2022, 27:e410-9. 10.1093\/oncolo\/oyac056","journal-title":"Oncologist"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.6515\/ACS.202201_38(1).20210830B","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated cardiovascular toxicities","volume":"38","author":"Wu NC","year":"2022","unstructured":"Wu NC, Feng YH, Kuo YH, et al.. Clinical features and outcomes of immune checkpoint inhibitor-associated cardiovascular toxicities. Acta Cardiol Sin. 2022, 38:39-46. 10.6515\/ACS.202201_38(1).20210830B","journal-title":"Acta Cardiol Sin"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01808","article-title":"Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors","volume":"40","author":"Laenens D","year":"2022","unstructured":"Laenens D, Yu Y, Santens B, et al.. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022, 40:3430-8. 10.1200\/JCO.21.01808","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.969942","article-title":"Cardiovascular adverse events induced by immune checkpoint inhibitors: a real world study from 2018 to 2022","volume":"9","author":"Wu S","year":"2022","unstructured":"Wu S, Bai H, Zhang L, et al.. Cardiovascular adverse events induced by immune checkpoint inhibitors: a real world study from 2018 to 2022. Front Cardiovasc Med. 2022, 9:969942. 10.3389\/fcvm.2022.969942","journal-title":"Front Cardiovasc Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-022-00147-w","article-title":"The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : including myocarditis and the new entity of non inflammatory left ventricular dysfunction","volume":"8","author":"Andres MS","year":"2022","unstructured":"Andres MS, Ramalingam S, Rosen SD, et al.. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : including myocarditis and the new entity of non inflammatory left ventricular dysfunction. Cardiooncology. 2022, 8:21. 10.1186\/s40959-022-00147-w","journal-title":"Cardiooncology"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-022-00149-8","article-title":"Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study","volume":"8","author":"Wang C","year":"2022","unstructured":"Wang C, Zoungas S, Yan M, et al.. Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study. Cardiooncology. 2022, 8:23. 10.1186\/s40959-022-00149-8","journal-title":"Cardiooncology"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.21-657","article-title":"Atherosclerotic progression is related to immune-related adverse events","volume":"63","author":"Kurozumi A","year":"2022","unstructured":"Kurozumi A, Sakamoto K, Nakagawa T, et al.. Atherosclerotic progression is related to immune-related adverse events. Int Heart J. 2022, 63:293-8. 10.1536\/ihj.21-657","journal-title":"Int Heart J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyac150","article-title":"The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations","volume":"52","author":"Chiang CH","year":"2022","unstructured":"Chiang CH, Chiang CH, Ma KS, et al.. The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations. Jpn J Clin Oncol. 2022, 52:1389-98. 10.1093\/jjco\/hyac150","journal-title":"Jpn J Clin Oncol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.878211","article-title":"A prospective study to detect immune checkpoint inhibitors associated with myocarditis among patients treated for lung cancer","volume":"9","author":"Faubry C","year":"2022","unstructured":"Faubry C, Faure M, Toublanc AC, et al.. A prospective study to detect immune checkpoint inhibitors associated with myocarditis among patients treated for lung cancer. Front Cardiovasc Med. 2022, 9:878211. 10.3389\/fcvm.2022.878211","journal-title":"Front Cardiovasc Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.10.010","article-title":"Cardiovascular risks of chemo-immunotherapy for lung cancer: a population-based cohort study","volume":"174","author":"Chan JS","year":"2022","unstructured":"Chan JS, Tang P, Ng K, et al.. Cardiovascular risks of chemo-immunotherapy for lung cancer: a population-based cohort study. Lung Cancer. 2022, 174:67-70. 10.1016\/j.lungcan.2022.10.010","journal-title":"Lung Cancer"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-021-00128-5","article-title":"Adverse cardiovascular complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched cohort study with competing risk analysis","volume":"8","author":"Zhou J","year":"2022","unstructured":"Zhou J, Lee S, Lakhani I, et al.. Adverse cardiovascular complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched cohort study with competing risk analysis. Cardiooncology. 2022, 8:5. 10.1186\/s40959-021-00128-5","journal-title":"Cardiooncology"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.4022\/jafib.2461","article-title":"Incidence of cancer treatment induced arrhythmia associated with immune checkpoint inhibitors","volume":"13","author":"Joseph L","year":"2021","unstructured":"Joseph L, C Nickel A, Patel A, F Saba N, R Leon A, F El-Chami M, M Merchant F. Incidence of cancer treatment induced arrhythmia associated with immune checkpoint inhibitors. J Atr Fibrillation. 2021, 13:2461. 10.4022\/jafib.2461","journal-title":"J Atr Fibrillation"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-021-00097-9","article-title":"Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center","volume":"7","author":"Waheed N","year":"2021","unstructured":"Waheed N, Fradley MG, DeRemer DL, et al.. Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardiooncology. 2021, 7:10. 10.1186\/s40959-021-00097-9","journal-title":"Cardiooncology"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100252","article-title":"Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States","volume":"6","author":"Jain P","year":"2021","unstructured":"Jain P, Gutierrez Bugarin J, Guha A, et al.. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open. 2021, 6:100252. 10.1016\/j.esmoop.2021.100252","journal-title":"ESMO Open"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002553","article-title":"Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Puzanov I","year":"2021","unstructured":"Puzanov I, Subramanian P, Yatsynovich YV, et al.. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer. 2021, 9:10.1136\/jitc-2021-002553","journal-title":"J Immunother Cancer"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002545","article-title":"Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach","volume":"9","author":"Heilbroner SP","year":"2021","unstructured":"Heilbroner SP, Few R, Mueller J, et al.. Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach. J Immunother Cancer. 2021, 9:10.1136\/jitc-2021-002545","journal-title":"J Immunother Cancer"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong J","year":"2021","unstructured":"Gong J, Drobni ZD, Zafar A, et al.. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021, 9:10.1136\/jitc-2021-002771","journal-title":"J Immunother Cancer"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman TA","year":"2021","unstructured":"Sussman TA, Li H, Hobbs B, Funchain P, McCrae KR, Khorana AA. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. J Immunother Cancer. 2021, 9:10.1136\/jitc-2020-001719","journal-title":"J Immunother Cancer"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik F","year":"2021","unstructured":"Moik F, Chan WE, Wiedemann S, et al.. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2021, 137:1669-78. 10.1182\/blood.2020007878","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2021.06.018","article-title":"Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: a retrospective multicentric cohort study","volume":"205","author":"Desch\u00eanes-Simard X","year":"2021","unstructured":"Desch\u00eanes-Simard X, Richard C, Galland L, et al.. Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: a retrospective multicentric cohort study. Thromb Res. 2021, 205:29-39. 10.1016\/j.thromres.2021.06.018","journal-title":"Thromb Res"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.07.005","article-title":"Characterization of immune checkpoint inhibitor-related cardiotoxicity in lung cancer patients from a rural setting","volume":"2","author":"Moey MY","year":"2020","unstructured":"Moey MY, Tomdio AN, McCallen JD, et al.. Characterization of immune checkpoint inhibitor-related cardiotoxicity in lung cancer patients from a rural setting. JACC CardioOncol. 2020, 2:491-502. 10.1016\/j.jaccao.2020.07.005","journal-title":"JACC CardioOncol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2019.11.080","article-title":"Myocardial and pericardial toxicity associated with immune checkpoint inhibitors in cancer patients","volume":"2","author":"Chahine J","year":"2020","unstructured":"Chahine J, Collier P, Maroo A, Tang WH, Klein AL. Myocardial and pericardial toxicity associated with immune checkpoint inhibitors in cancer patients. JACC Case Rep. 2020, 2:191-9. 10.1016\/j.jaccas.2019.11.080","journal-title":"JACC Case Rep"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"D'Souza M","year":"2021","unstructured":"D'Souza M, Nielsen D, Svane IM, et al.. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2021, 42:1621-31. 10.1093\/eurheartj\/ehaa884","journal-title":"Eur Heart J"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01386-y","article-title":"Incidence of pericardial effusion in patients with advanced non-small cell lung cancer receiving immunotherapy","volume":"37","author":"Canale ML","year":"2020","unstructured":"Canale ML, Camerini A, Casolo G, et al.. Incidence of pericardial effusion in patients with advanced non-small cell lung cancer receiving immunotherapy. Adv Ther. 2020, 37:3178-84. 10.1007\/s12325-020-01386-y","journal-title":"Adv Ther"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.02.016","article-title":"Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors","volume":"125","author":"Oren O","year":"2020","unstructured":"Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL. Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors. Am J Cardiol. 2020, 125:1920-6. 10.1016\/j.amjcard.2020.02.016","journal-title":"Am J Cardiol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2020.03.08","article-title":"A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China","volume":"9","author":"Wang F","year":"2020","unstructured":"Wang F, Sun X, Qin S, Hua H, Liu X, Yang L, Yang M. A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China. Chin Clin Oncol. 2020, 9:16. 10.21037\/cco.2020.03.08","journal-title":"Chin Clin Oncol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni ZD","year":"2020","unstructured":"Drobni ZD, Alvi RM, Taron J, et al.. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020, 142:2299-311. 10.1161\/CIRCULATIONAHA.120.049981","journal-title":"Circulation"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010067","article-title":"Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients","volume":"12","author":"Nichetti F","year":"2019","unstructured":"Nichetti F, Ligorio F, Zattarin E, et al.. Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients. Cancers (Basel). 2019, 12:67. 10.3390\/cancers12010067","journal-title":"Cancers (Basel)"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.11.013","article-title":"Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer","volume":"1","author":"Chitturi KR","year":"2019","unstructured":"Chitturi KR, Xu J, Araujo-Gutierrez R, et al.. Immune checkpoint inhibitor-related adverse cardiovascular events in patients with lung cancer. JACC CardioOncol. 2019, 1:182-92. 10.1016\/j.jaccao.2019.11.013","journal-title":"JACC CardioOncol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study","volume":"120","author":"Bar J","year":"2019","unstructured":"Bar J, Markel G, Gottfried T, et al.. Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study. Eur J Cancer. 2019, 120:122-31. 10.1016\/j.ejca.2019.06.021","journal-title":"Eur J Cancer"},{"key":"ref63","article-title":"Critical appraisal tools for use in JBI systematic reviews: checklist for analytical cross-sectional studies. Published","year":"2020","unstructured":"JBI Checklist for Analytical Cross Sectional Studies. Critical Appraisal tools for use in JBI Systematic Reviews. JBI, Kv\u00e6rndrup, Denmark; 2020. http:\/\/jbi.global\/sites\/default\/files\/2020-08\/Checklist_for_Analytical_Cross_Sectional_Studies.pdf."},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas A","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018, 359:1350-5. 10.1126\/science.aar4060","journal-title":"Science"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.616505","article-title":"Cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on FAERS","volume":"12","author":"Chen C","year":"2021","unstructured":"Chen C, Chen T, Liang J, et al.. Cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on FAERS. Front Pharmacol. 2021, 12:616505. 10.3389\/fphar.2021.616505","journal-title":"Front Pharmacol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-021-00106-x","article-title":"A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors","volume":"7","author":"Lal JC","year":"2021","unstructured":"Lal JC, Brown SA, Collier P, Cheng F. A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors. Cardiooncology. 2021, 7:19. 10.1186\/s40959-021-00106-x","journal-title":"Cardiooncology"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01086-8","article-title":"Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in EudraVigilance","volume":"44","author":"Mascolo A","year":"2021","unstructured":"Mascolo A, Scavone C, Ferrajolo C, et al.. Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in EudraVigilance. Drug Saf. 2021, 44:957-71. 10.1007\/s40264-021-01086-8","journal-title":"Drug Saf"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.043","article-title":"Cardiotoxicity of immune checkpoint inhibitors: a systematic review and meta-analysis of randomised clinical trials","volume":"148","author":"Agostinetto E","year":"2021","unstructured":"Agostinetto E, Eiger D, Lambertini M, et al.. Cardiotoxicity of immune checkpoint inhibitors: a systematic review and meta-analysis of randomised clinical trials. Eur J Cancer. 2021, 148:76-91. 10.1016\/j.ejca.2021.01.043","journal-title":"Eur J Cancer"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1006860","article-title":"Cardiotoxicity of immune checkpoint inhibitors: a frequency network meta-analysis","volume":"13","author":"Liu M","year":"2022","unstructured":"Liu M, Cheng X, Ni R, Zheng B, Huang S, Yang J. Cardiotoxicity of immune checkpoint inhibitors: a frequency network meta-analysis. Front Immunol. 2022, 13:1006860. 10.3389\/fimmu.2022.1006860","journal-title":"Front Immunol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S191022","article-title":"Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"15","author":"Jiang Y","year":"2019","unstructured":"Jiang Y, Zhang N, Pang H, Gao X, Zhang H. Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis. Ther Clin Risk Manag. 2019, 15:293-302. 10.2147\/TCRM.S191022","journal-title":"Ther Clin Risk Manag"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.645245","article-title":"Risk of cardiac adverse events in patients treated with immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"11","author":"Hu J","year":"2021","unstructured":"Hu J, Tian R, Ma Y, Zhen H, Ma X, Su Q, Cao B. Risk of cardiac adverse events in patients treated with immune checkpoint inhibitor regimens: a systematic review and meta-analysis. Front Oncol. 2021, 11:645245. 10.3389\/fonc.2021.645245","journal-title":"Front Oncol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0118","article-title":"Cardiotoxicity with immune system targeting drugs: a meta-analysis of anti-PD\/PD-L1 immunotherapy randomized clinical trials","volume":"11","author":"Rahouma M","year":"2019","unstructured":"Rahouma M, Karim NA, Baudo M, et al.. Cardiotoxicity with immune system targeting drugs: a meta-analysis of anti-PD\/PD-L1 immunotherapy randomized clinical trials. Immunotherapy. 2019, 11:725-35. 10.2217\/imt-2018-0118","journal-title":"Immunotherapy"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2017.1344099","article-title":"Risk of cardiac death among cancer survivors in the United States: a SEER database analysis","volume":"17","author":"Abdel-Rahman O","year":"2017","unstructured":"Abdel-Rahman O. Risk of cardiac death among cancer survivors in the United States: a SEER database analysis. Expert Rev Anticancer Ther. 2017, 17:873-8. 10.1080\/14737140.2017.1344099","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.986357","article-title":"Cardiac arrhythmias associated with immune checkpoint inhibitors: a comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Wang F","year":"2022","unstructured":"Wang F, Wei Q, Wu X. Cardiac arrhythmias associated with immune checkpoint inhibitors: a comprehensive disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol. 2022, 13:986357. 10.3389\/fphar.2022.986357","journal-title":"Front Pharmacol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12320","article-title":"Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis","volume":"42","author":"Xu Y","year":"2022","unstructured":"Xu Y, Song Y, Liu X, et al.. Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis. Cancer Commun (Lond). 2022, 42:902-5. 10.1002\/cac2.12320","journal-title":"Cancer Commun (Lond)"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272022","article-title":"Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy","volume":"17","author":"Cone EB","year":"2022","unstructured":"Cone EB, Haeuser L, Reese SW, et al.. Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS One. 2022, 17:e0272022. 10.1371\/journal.pone.0272022","journal-title":"PLoS One"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1497","article-title":"Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication","volume":"21","author":"Ederhy S","year":"2019","unstructured":"Ederhy S, Dolladille C, Thuny F, Alexandre J, Cohen A. Takotsubo syndrome in patients with cancer treated with immune checkpoint inhibitors: a new adverse cardiac complication. Eur J Heart Fail. 2019, 21:945-7. 10.1002\/ejhf.1497","journal-title":"Eur J Heart Fail"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000261","article-title":"Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"8","author":"Dolladille C","year":"2020","unstructured":"Dolladille C, Ederhy S, Allouche S, et al.. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020, 8:10.1136\/jitc-2019-000261","journal-title":"J Immunother Cancer"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier M","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, et al.. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017, 136:2085-7. 10.1161\/CIRCULATIONAHA.117.030571","journal-title":"Circulation"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.2174\/1573403x11666141122220003","article-title":"Disparities in cardiovascular disease risk in the United States","volume":"11","author":"Graham G","year":"2015","unstructured":"Graham G. Disparities in cardiovascular disease risk in the United States. Curr Cardiol Rev. 2015, 11:238-45. 10.2174\/1573403x11666141122220003","journal-title":"Curr Cardiol Rev"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak R","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021, 26:1052-61. 10.1002\/onco.13931","journal-title":"Oncologist"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.100791","article-title":"Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature","volume":"8","author":"Boutros A","year":"2023","unstructured":"Boutros A, Bottini A, Rossi G, et al.. Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature. ESMO Open. 2023, 8:100791. 10.1016\/j.esmoop.2023.100791","journal-title":"ESMO Open"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura H","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, et al.. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001, 291:319-22. 10.1126\/science.291.5502.319","journal-title":"Science"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.4.2513","article-title":"Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice","volume":"181","author":"Lucas JA","year":"2008","unstructured":"Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol. 2008, 181:2513-21. 10.4049\/jimmunol.181.4.2513","journal-title":"J Immunol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S185202","article-title":"Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges","volume":"11","author":"Martin Huertas R","year":"2019","unstructured":"Martin Huertas R, Saavedra Serrano C, Perna C, Ferrer G\u00f3mez A, Alonso Gordoa T. Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges. Cancer Manag Res. 2019, 11:4541-8. 10.2147\/CMAR.S185202","journal-title":"Cancer Manag Res"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli H","year":"2015","unstructured":"L\u00e4ubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015, 3:11. 10.1186\/s40425-015-0057-1","journal-title":"J Immunother Cancer"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003514","article-title":"Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab","volume":"9","author":"Tadokoro T","year":"2016","unstructured":"Tadokoro T, Keshino E, Makiyama A, Sasaguri T, Ohshima K, Katano H, Mohri M. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ Heart Fail. 2016, 9:10.1161\/CIRCHEARTFAILURE.116.003514","journal-title":"Circ Heart Fail"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072399","article-title":"Programmed cell death-1: programmed cell death-ligand 1 interaction protects human cardiomyocytes against T-cell mediated inflammation and apoptosis response in vitro","volume":"21","author":"Tay WT","year":"2020","unstructured":"Tay WT, Fang YH, Beh ST, Liu YW, Hsu LW, Yen CJ, Liu PY. Programmed cell death-1: programmed cell death-ligand 1 interaction protects human cardiomyocytes against T-cell mediated inflammation and apoptosis response in vitro. Int J Mol Sci. 2020, 21:2399. 10.3390\/ijms21072399","journal-title":"Int J Mol Sci"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.08.033","article-title":"Cardiotoxic mechanisms of cancer immunotherapy - a systematic review","volume":"323","author":"Lobenwein D","year":"2021","unstructured":"Lobenwein D, Kocher F, Dobner S, Gollmann-Tepek\u00f6yl\u00fc C, Holfeld J. Cardiotoxic mechanisms of cancer immunotherapy - a systematic review. Int J Cardiol. 2021, 323:179-87. 10.1016\/j.ijcard.2020.08.033","journal-title":"Int J Cardiol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.09.041","article-title":"Cardiotoxicity in cancer immune-checkpoint therapy: mechanisms, clinical evidence, and management strategies","volume":"344","author":"Sun JY","year":"2021","unstructured":"Sun JY, Qu Q, Lou YX, Hua Y, Sun GZ, Sun W, Kong XQ. Cardiotoxicity in cancer immune-checkpoint therapy: mechanisms, clinical evidence, and management strategies. Int J Cardiol. 2021, 344:170-8. 10.1016\/j.ijcard.2021.09.041","journal-title":"Int J Cardiol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang L","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M, et al.. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020, 141:2031-4. 10.1161\/CIRCULATIONAHA.119.044703","journal-title":"Circulation"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi JJ","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018, 391:933. 10.1016\/S0140-6736(18)30533-6","journal-title":"Lancet"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105866","article-title":"Myocarditis following the use of different immune checkpoint inhibitor regimens: a real-world analysis of post-marketing surveillance data","volume":"76","author":"Fan Q","year":"2019","unstructured":"Fan Q, Hu Y, Yang C, Zhao B. Myocarditis following the use of different immune checkpoint inhibitor regimens: a real-world analysis of post-marketing surveillance data. Int Immunopharmacol. 2019, 76:105866. 10.1016\/j.intimp.2019.105866","journal-title":"Int Immunopharmacol"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood TG","year":"2017","unstructured":"Norwood TG, Westbrook BC, Johnson DB, et al.. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer. 2017, 5:91. 10.1186\/s40425-017-0296-4","journal-title":"J Immunother Cancer"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2019.11.076","article-title":"Evolution of immune checkpoint blockade-induced myocarditis over 2 years","volume":"2","author":"Norwood TG","year":"2020","unstructured":"Norwood TG, Lenneman CA, Westbrook BC, Litovsky SH, McKee SB, Conry RM. Evolution of immune checkpoint blockade-induced myocarditis over 2 years. JACC Case Rep. 2020, 2:203-9. 10.1016\/j.jaccas.2019.11.076","journal-title":"JACC Case Rep"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-232920","article-title":"Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease","volume":"13","author":"Leaver PJ","year":"2020","unstructured":"Leaver PJ, Jang HS, Vernon ST, Fernando SL. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease. BMJ Case Rep. 2020, 13:e232920. 10.1136\/bcr-2019-232920","journal-title":"BMJ Case Rep"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02927-x","article-title":"Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases","volume":"145","author":"Atallah-Yunes SA","year":"2019","unstructured":"Atallah-Yunes SA, Kadado AJ, Kaufman GP, Hernandez-Montfort J. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol. 2019, 145:1527-57. 10.1007\/s00432-019-02927-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra S","year":"2018","unstructured":"Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist. 2018, 23:879-86. 10.1634\/theoncologist.2018-0130","journal-title":"Oncologist"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v12.i11.584","article-title":"Cardiac adverse events of immune checkpoint inhibitors in oncology patients: a systematic review and meta-analysis","volume":"12","author":"Nso N","year":"2020","unstructured":"Nso N, Antwi-Amoabeng D, Beutler BD, et al.. Cardiac adverse events of immune checkpoint inhibitors in oncology patients: a systematic review and meta-analysis. World J Cardiol. 2020, 12:584-98. 10.4330\/wjc.v12.i11.584","journal-title":"World J Cardiol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2019.11.035","article-title":"Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event","volume":"36","author":"Cautela J","year":"2020","unstructured":"Cautela J, Rouby F, Salem JE, et al.. Acute coronary syndrome with immune checkpoint inhibitors: a proof-of-concept case and pharmacovigilance analysis of a life-threatening adverse event. Can J Cardiol. 2020, 36:476-81. 10.1016\/j.cjca.2019.11.035","journal-title":"Can J Cardiol"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01246-x","article-title":"Evaluation of cardiac adverse events with nivolumab using a Japanese real-world database","volume":"43","author":"Kanbayashi Y","year":"2023","unstructured":"Kanbayashi Y, Shimizu T, Anzai M, Kawai R, Uchida M. Evaluation of cardiac adverse events with nivolumab using a Japanese real-world database. Clin Drug Investig. 2023, 43:177-84. 10.1007\/s40261-023-01246-x","journal-title":"Clin Drug Investig"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"Adler Y","year":"2015","unstructured":"Adler Y, Charron P, Imazio M, et al.. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015, 36:2921-64. 10.1093\/eurheartj\/ehv318","journal-title":"Eur Heart J"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2019-315852","article-title":"Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes","volume":"106","author":"Imazio M","year":"2020","unstructured":"Imazio M, Colopi M, De Ferrari GM. Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes. Heart. 2020, 106:569-74. 10.1136\/heartjnl-2019-315852","journal-title":"Heart"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE- 010): a randomised controlled trial","volume":"387","author":"Herbst RS","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, et al.. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE- 010): a randomised controlled trial. Lancet. 2016, 387:1540-50. 10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.02.026","article-title":"Immune checkpoint inhibitor-associated pericarditis","volume":"14","author":"Altan M","year":"2019","unstructured":"Altan M, Toki MI, Gettinger SN, et al.. Immune checkpoint inhibitor-associated pericarditis. J Thorac Oncol. 2019, 14:1102-8. 10.1016\/j.jtho.2019.02.026","journal-title":"J Thorac Oncol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.749834","article-title":"Immune checkpoint inhibitor-induced pericarditis and encephalitis in a patient treated with ipilimumab and nivolumab for metastatic melanoma: a case report and review of the literature","volume":"11","author":"Braden J","year":"2021","unstructured":"Braden J, Lee JH. Immune checkpoint inhibitor-induced pericarditis and encephalitis in a patient treated with ipilimumab and nivolumab for metastatic melanoma: a case report and review of the literature. Front Oncol. 2021, 11:749834. 10.3389\/fonc.2021.749834","journal-title":"Front Oncol"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0223","article-title":"PD-1\/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review","volume":"14","author":"Li H","year":"2022","unstructured":"Li H, Han D, Zhang L, et al.. PD-1\/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review. Immunotherapy. 2022, 14:577-92. 10.2217\/imt-2021-0223","journal-title":"Immunotherapy"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.908173","article-title":"Cardiovascular toxicity with PD-1\/PD-L1 inhibitors in cancer patients: a systematic review and meta-analysis","volume":"13","author":"Liu S","year":"2022","unstructured":"Liu S, Gao W, Ning Y, Zou X, Zhang W, Zeng L, Liu J. Cardiovascular toxicity with PD-1\/PD-L1 inhibitors in cancer patients: a systematic review and meta-analysis. Front Immunol. 2022, 13:908173. 10.3389\/fimmu.2022.908173","journal-title":"Front Immunol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon AR","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018, 19:447-58. 10.1016\/S1470-2045(18)30457-1","journal-title":"Lancet Oncol"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0255-17","article-title":"Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring","volume":"57","author":"Katsume Y","year":"2018","unstructured":"Katsume Y, Isawa T, Toi Y, Fukuda R, Kondo Y, Sugawara S, Ootomo T. Complete atrioventricular block associated with pembrolizumab-induced acute myocarditis: the need for close cardiac monitoring. Intern Med. 2018, 57:3157-62. 10.2169\/internalmedicine.0255-17","journal-title":"Intern Med"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001287","article-title":"Pembrolizumab-induced myocarditis leading to persistent atrial arrhythmias and a cascade of complications: a therapeutic dilemma","volume":"28","author":"Kichloo A","year":"2020","unstructured":"Kichloo A, Aljadah M, Vipparla N, Jamal S, Kanjwal K. Pembrolizumab-induced myocarditis leading to persistent atrial arrhythmias and a cascade of complications: a therapeutic dilemma. Am J Ther. 2020, 28:e606-8. 10.1097\/MJT.0000000000001287","journal-title":"Am J Ther"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2020.09.006","article-title":"PD-1\/PD-L1 inhibitors and cardiotoxicity: molecular, etiological and management outlines","volume":"29","author":"Safi M","year":"2021","unstructured":"Safi M, Ahmed H, Al-Azab M, et al.. PD-1\/PD-L1 inhibitors and cardiotoxicity: molecular, etiological and management outlines. J Adv Res. 2021, 29:45-54. 10.1016\/j.jare.2020.09.006","journal-title":"J Adv Res"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2391","article-title":"Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma","volume":"4","author":"Shoushtari AN","year":"2018","unstructured":"Shoushtari AN, Friedman CF, Navid-Azarbaijani P, et al.. Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol. 2018, 4:98-101. 10.1001\/jamaoncol.2017.2391","journal-title":"JAMA Oncol"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu YB","year":"2017","unstructured":"Hu YB, Zhang Q, Li HJ, et al.. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2017, 6:S8-S20. 10.21037\/tlcr.2017.12.10","journal-title":"Transl Lung Cancer Res"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8093","article-title":"A case of acute heart failure following immunotherapy for metastatic lung cancer","volume":"12","author":"Al-Obaidi A","year":"2020","unstructured":"Al-Obaidi A, Parker NA, Choucair K, Alderson J, Deutsch JM. A case of acute heart failure following immunotherapy for metastatic lung cancer. Cureus. 2020, 12:e8093. 10.7759\/cureus.8093","journal-title":"Cureus"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4550-20","article-title":"Development of severe heart failure in a patient with squamous non-small-cell lung cancer during nivolumab treatment","volume":"59","author":"Samejima Y","year":"2020","unstructured":"Samejima Y, Iuchi A, Kanai T, et al.. Development of severe heart failure in a patient with squamous non-small-cell lung cancer during nivolumab treatment. Intern Med. 2020, 59:2003-8. 10.2169\/internalmedicine.4550-20","journal-title":"Intern Med"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas N","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020, 9:e013757. 10.1161\/JAHA.119.013757","journal-title":"J Am Heart Assoc"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0048-2","article-title":"Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome","volume":"3","author":"Geisler BP","year":"2015","unstructured":"Geisler BP, Raad RA, Esaian D, Sharon E, Schwartz DR. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer. 2015, 3:4. 10.1186\/s40425-015-0048-2","journal-title":"J Immunother Cancer"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2017.11.036","article-title":"Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors","volume":"11","author":"Ederhy S","year":"2018","unstructured":"Ederhy S, Cautela J, Ancedy Y, Escudier M, Thuny F, Cohen A. Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC Cardiovasc Imaging. 2018, 11:1187-90. 10.1016\/j.jcmg.2017.11.036","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000190","article-title":"Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy","volume":"41","author":"Tajmir-Riahi A","year":"2018","unstructured":"Tajmir-Riahi A, Bergmann T, Schmid M, Agaimy A, Schuler G, Heinzerling L. Life-threatening autoimmune cardiomyopathy reproducibly induced in a patient by checkpoint inhibitor therapy. J Immunother. 2018, 41:35-8. 10.1097\/CJI.0000000000000190","journal-title":"J Immunother"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001026","article-title":"Takotsubo cardiomyopathy as epiphenomenon of cardiotoxicity in patients with cancer: a meta-summary of case reports","volume":"78","author":"Carbone A","year":"2021","unstructured":"Carbone A, Bottino R, Russo V, et al.. Takotsubo cardiomyopathy as epiphenomenon of cardiotoxicity in patients with cancer: a meta-summary of case reports. J Cardiovasc Pharmacol. 2021, 78:e20-9. 10.1097\/FJC.0000000000001026","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092637","article-title":"Takotsubo cardiomyopathy in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-summary of included cases","volume":"15","author":"Trontzas IP","year":"2023","unstructured":"Trontzas IP, Vathiotis IA, Kyriakoulis KG, et al.. Takotsubo cardiomyopathy in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-summary of included cases. Cancers (Basel). 2023, 15:2637. 10.3390\/cancers15092637","journal-title":"Cancers (Basel)"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-019-0042-9","article-title":"Takotsubo cardiomyopathy in cancer patients","volume":"5","author":"Desai A","year":"2019","unstructured":"Desai A, Noor A, Joshi S, Kim AS. Takotsubo cardiomyopathy in cancer patients. Cardiooncology. 2019, 5:7. 10.1186\/s40959-019-0042-9","journal-title":"Cardiooncology"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.5114\/amsad.2017.72531","article-title":"A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) - systemic inflammatory response syndrome after use of pembrolizumab","volume":"2","author":"Nykl R","year":"2017","unstructured":"Nykl R, Fischer O, Vykoupil K, Taborsky M. A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) - systemic inflammatory response syndrome after use of pembrolizumab. Arch Med Sci Atheroscler Dis. 2017, 2:e100-2. 10.5114\/amsad.2017.72531","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-018-0579-9","article-title":"Coronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report and review of the literature and international registries","volume":"13","author":"Ferreira M","year":"2018","unstructured":"Ferreira M, Pichon E, Carmier D, et al.. Coronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report and review of the literature and international registries. Target Oncol. 2018, 13:509-15. 10.1007\/s11523-018-0579-9","journal-title":"Target Oncol"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/20.037","article-title":"Possible precipitation of acute coronary syndrome with immune checkpoint blockade: a case report","volume":"24","author":"Masson R","year":"2020","unstructured":"Masson R, Manthripragada G, Liu R, Tavakoli J, Mok K. Possible precipitation of acute coronary syndrome with immune checkpoint blockade: a case report. Perm J. 2020, 24:1. 10.7812\/TPP\/20.037","journal-title":"Perm J"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu DX","year":"2011","unstructured":"Bu DX, Tarrio M, Maganto-Garcia E, et al.. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol. 2011, 31:1100-7. 10.1161\/ATVBAHA.111.224709","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice","volume":"117","author":"Gotsman I","year":"2007","unstructured":"Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH. Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice. J Clin Invest. 2007, 117:2974-82. 10.1172\/JCI31344","journal-title":"J Clin Invest"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e19392","article-title":"Immune landscape and regulatory mechanisms in human atherosclerotic coronary plaques: evidence from single-cell and bulk transcriptomics","volume":"9","author":"Liang WL","year":"2023","unstructured":"Liang WL, Liao HL, Liang B. Immune landscape and regulatory mechanisms in human atherosclerotic coronary plaques: evidence from single-cell and bulk transcriptomics. Heliyon. 2023, 9:e19392. 10.1016\/j.heliyon.2023.e19392","journal-title":"Heliyon"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille C","year":"2021","unstructured":"Dolladille C, Akroun J, Morice PM, et al.. Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J. 2021, 42:4964-77. 10.1093\/eurheartj\/ehab618","journal-title":"Eur Heart J"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review","volume":"6","author":"Lehmann LH","year":"2021","unstructured":"Lehmann LH, Cautela J, Palaskas N, et al.. Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. JAMA Cardiol. 2021, 6:1329-37. 10.1001\/jamacardio.2021.2241","journal-title":"JAMA Cardiol"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany S","year":"2021","unstructured":"Waliany S, Neal JW, Reddy S, et al.. Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors. JACC CardioOncol. 2021, 3:137-9. 10.1016\/j.jaccao.2021.01.004","journal-title":"JACC CardioOncol"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2504","article-title":"Acute lower limb ischaemia and diabetes in a patient treated with anti-PD1 monoclonal antibody for metastatic melanoma","volume":"97","author":"Thoreau B","year":"2017","unstructured":"Thoreau B, Gouaillier-Vulcain F, Machet L, et al.. Acute lower limb ischaemia and diabetes in a patient treated with anti-PD1 monoclonal antibody for metastatic melanoma. Acta Derm Venereol. 2017, 97:408-9. 10.2340\/00015555-2504","journal-title":"Acta Derm Venereol"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder FI","year":"2021","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N, et al.. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021, 137:1959-69. 10.1182\/blood.2020007338","journal-title":"Blood"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Hisada Y","year":"2017","unstructured":"Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017, 130:1499-506. 10.1182\/blood-2017-03-743211","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/376034-cardiovascular-toxicity-associated-with-immune-checkpoint-inhibitors-interpreting-the-discrepancy-between-clinical-trials-and-real-world-data","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T18:37:24Z","timestamp":1751308644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/376034-cardiovascular-toxicity-associated-with-immune-checkpoint-inhibitors-interpreting-the-discrepancy-between-clinical-trials-and-real-world-data"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":135,"URL":"https:\/\/doi.org\/10.7759\/cureus.87049","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}